ClinicalTrials.Veeva

Menu

Metabonomic of Patients With Hepatitis B Cirrhosis Complicated With Sarcopenia.

Q

Qingdao University

Status

Completed

Conditions

Sarcopenia

Treatments

Diagnostic Test: CT at the level of the third lumbar vertebra (L3)

Study type

Observational

Funder types

Other

Identifiers

NCT05041348
QYFYWZLL26461

Details and patient eligibility

About

Sarcopenia is a common complication in liver cirrhosis patients and has been confirmed that associated with poor prognosis. China has the world's largest burden of hepatitis B virus-related liver cirrhosis (HBV-related liver cirrhosis). However, the relationship between HBV-related liver cirrhosis patients with muscle mass loss and normal muscle mass is remain largely unknown. Our study aimed to reveal the metabolic profile and identify potential biomarkers of muscle mass loss in HBV-related liver cirrhosis.

Enrollment

60 patients

Sex

All

Ages

18 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. the diagnostic criteria for decompensation of liver cirrhosis of chronic viral hepatitis B formulated according to the Guidelines for Diagnosis and Treatment of Liver Cirrhosis issued by the Chinese Society of Hepatology in 2019
  2. The diagnosis of muscle mass loss conforms to SMI less than 46.96 cm²/m² for males and less than 32.46 cm²/m² for females
  3. Patients aged between 18 and 60 years old
  4. Patients with no history of drinking or abstinence for more than 1 year
  5. Voluntary participants with informed consent

Exclusion criteria

  1. the etiology of cirrhosis without hepatitis B virus (HBV), such as cirrhosis, alcoholic cirrhosis, autoimmune cirrhosis, and so on; 2) the age of patients over 60 years old; 3) patients with acute, chronic and acute liver failure; 4) other diseases which can lead to the secondary muscle depletion, such as chronic disease in heart, lung, kidney, brain, and malignant tumor; 5) neurodegenerative diseases or muscle degenerative diseases; 6) perioperative patients; 7) patients without CT scan within 3 months; 8) patients who have exercise habits with the Physical Activity Rating Scale-3 (PARS-3) > 19 points

Trial design

60 participants in 3 patient groups

liver cirrhosis patients with muscle mass loss
Description:
The diagnosis of cirrhosis was made based on the combination of clinical and laboratory features or by liver histopathology. Skeletal muscle mass index (SMI), which was the ratio of lean tissue area to body height. Muscle mass loss was defined as an SMI less than 46.96 cm²/m² for males and less than 32.46 cm²/m² for females
Treatment:
Diagnostic Test: CT at the level of the third lumbar vertebra (L3)
liver cirrhosis patients with normal muscle mass
Description:
Skeletal muscle mass index (SMI) was not decreased in this group.
Treatment:
Diagnostic Test: CT at the level of the third lumbar vertebra (L3)
healthy group
Description:
People in healthy control group were excluded metabolic diseases (including diabetes, thyroid disorder, and so on) and other chronic diseases, according to their ultrasound and laboratory assessment.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems